BMRN Q2 2023 Earnings — BioMarin Pharmaceutical Inc. Revenue & Financial Results | Market Cap Arena

BMRNBioMarin Pharmaceutical Inc.

$12B

Q2 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$595M+11.5% YoY

Gross Profit

$465M78.1% margin

Operating Income

$66M11.0% margin

Net Income

$56M9.4% margin

EPS (Diluted)

$0.29

QoQ Revenue Growth

-0.2%

Cash Flow

Operating Cash Flow

$70M

Free Cash Flow

$47M

Stock-Based Comp.

$50M

Balance Sheet

Total Assets

$6.6B

Total Liabilities

$1.8B

Stockholders' Equity

$4.8B

Cash & Equivalents

$694M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$595M	$534M	+11.5%
Gross Profit	$465M	$411M	+13.1%
Operating Income	$66M	$39M	+67.5%
Net Income	$56M	$28M	+102.6%

Revenue Segments

Product

$585M58%

Enzyme Product

$421M41%

Royalty And Other

$11M1%